--- title: "Pep19 | PepTracker Pro" url: https://peptrackerpro.com/peptides/pep19 description: "An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. Aliases Pep-19 +3 more Evidence Low Evidence Last Updated 2026-06-13 Reading Time 4 min ## What It Is Pep19 is a synthetic version of a small intracellular peptide that occurs naturally inside human cells. It is being studied as a metabolic-health compound that works through the endocannabinoid system — the signaling network that helps regulate appetite, fat storage and breakdown (lipolysis), energy use, and sleep. Unlike the cannabinoid drugs of the 2000s (such as rimonabant, a CB1 antagonist withdrawn over psychiatric side effects), Pep19 is reported to act peripherally rather than crossing into the central nervous system, which its developers argue may avoid the mood and anxiety effects that doomed earlier CB1-targeted weight drugs. In a triple-blind, placebo-controlled early-stage clinical trial published in 2026 in Diabetes/Metabolism Research and Reviews, 24 adults with obesity (BMI 30–35) took a once-daily oral capsule at bedtime for 60 days. The 5 mg dose produced about a 17% reduction in visceral fat — the metabolically dangerous fat around the organs that is strongly linked to cardiovascular disease and type 2 diabetes — along with reductions in body weight and waist circumference, and crucially no change in lean body mass. Both the 2 mg and 5 mg doses improved sleep quality, and no side effects were reported. Preclinical mouse work showed Pep19 also helps convert energy-storing white fat into calorie-burning brown fat and improves blood sugar, cholesterol, and blood pressure. The compound was developed by Proteimax Biotechnology with researchers at the University of São Paulo (ICB-USP) and the Pennington Biomedical Research Center. The data are early — a single small trial — and Pep19 is not approved by any regulator and is not a compounded or marketed product. It is also not on the FDA's July 2026 PCAC compounding review list. Also known as: Pep-19, Pep 19, Proteimax Pep19, endocannabinoid metabolic peptide ## Why Researchers Study It Pep19 is interesting because it targets a different node than the dominant obesity drugs. GLP-1 and amylin therapies work largely through appetite suppression in the brain and can drive lean-mass loss alongside fat loss; ERR agonists and mitochondrial compounds target oxidative metabolism. Pep19 instead modulates the endocannabinoid system to act on fat storage and breakdown directly, and in its first human trial it preferentially reduced visceral fat while sparing lean mass and improving sleep — an unusual combination. It is also a test case for whether the endocannabinoid system, abandoned for weight loss after rimonabant's psychiatric side effects, can be re-approached safely with a peripherally acting peptide. The dual metabolic-plus-sleep signal is notable because poor sleep is itself a driver of obesity and metabolic dysfunction. ## Proposed Mechanisms - Acts on the endocannabinoid system to regulate appetite, lipolysis, and energy expenditure - Reported to act peripherally rather than centrally, aiming to avoid CNS/psychiatric effects seen with CB1 antagonists - Promotes browning of white adipose tissue (white-to-brown fat conversion) in preclinical models - Preferentially reduces visceral adipose tissue while sparing lean body mass (early human data) - Improves glycemic, lipid, and blood-pressure markers in preclinical models ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Clinical (early-stage RCT) | Triple-blind, placebo-controlled; 24 adults with obesity (BMI 30–35), 60 days, oral 2 mg or 5 mg at bedtime | 5 mg arm: ~17% reduction in visceral fat with no change in lean mass; reduced body weight and waist circumference; sleep quality improved at both doses; no adverse effects | Source: https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70056 | | Preclinical (mouse) | Diet-induced obesity models | Anti-obesity effects with improved blood glucose, cholesterol, and blood pressure; conversion of white fat to brown fat; no observed side effects | Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126752/ | ## Commonly Discussed Benefits Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Sleep: https://peptrackerpro.com/benefits/sleep Researching Pep19? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=pep19) ## Safety & Cautions - Human evidence is limited to one small early-stage trial (n=24, 60 days) — not confirmatory - Not approved by the FDA or any regulator; not a marketed or compounded product - Not on the FDA's July 2026 PCAC compounding review list - Long-term safety and durability of effect are unknown; larger and longer trials are needed - Endocannabinoid-targeting weight drugs have a difficult history (rimonabant was withdrawn for psychiatric effects); a peripheral mechanism is claimed but not yet established in large human studies - Most mechanistic data (white-to-brown fat conversion, lipid/glucose effects) come from mice, not humans ## Comparisons See how Pep19 compares to related peptides: Pep19 vs 5-Amino-1MQ: https://peptrackerpro.com/compare/pep19-vs-5-amino-1mq Pep19 vs Cagrilintide: https://peptrackerpro.com/compare/pep19-vs-cagrilintide Pep19 vs MOTS-c: https://peptrackerpro.com/compare/pep19-vs-mots-c Pep19 vs Retatrutide: https://peptrackerpro.com/compare/pep19-vs-retatrutide Pep19 vs Tesamorelin: https://peptrackerpro.com/compare/pep19-vs-tesamorelin ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Heimann A. et al. — Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults — Results From an Early-Stage Clinical Trial. Diabetes/Metabolism Research and Reviews, 2026 PubMed (https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70056) 2. [2] Pep19 early-stage clinical trial — PMC full text PubMed (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126752/) 3. [3] Agência FAPESP — Study points out that a synthetic molecule helps reduce visceral fat and improve sleep (2025) PubMed (https://agencia.fapesp.br/study-points-out-that-a-synthetic-molecule-helps-reduce-visceral-fat-and-improve-sleep/55687) ### Keep researching in the app - Log Pep19 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=pep19 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/5-amino-1mq \+ Compare: https://peptrackerpro.com/compare?select=5-amino-1mq Track in App: https://app.peptrackerpro.com/?add=5-amino-1mq ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### MOTS-c Low Evidence A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Longevity (https://peptrackerpro.com/benefits/longevity)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+2 more View Details: https://peptrackerpro.com/peptides/mots-c \+ Compare: https://peptrackerpro.com/compare?select=mots-c Track in App: https://app.peptrackerpro.com/?add=mots-c ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Tesamorelin High Evidence A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Metabolism: https://peptrackerpro.com/benefits/metabolism Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/tesamorelin \+ Compare: https://peptrackerpro.com/compare?select=tesamorelin Track in App: https://app.peptrackerpro.com/?add=tesamorelin ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Pep19", "description": "An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss.", "url": "https://peptrackerpro.com/peptides/pep19", "lastReviewed": "2026-06-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Pep19", "item": "https://peptrackerpro.com/peptides/pep19" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People comparing newer obesity approaches with GLP-1 and amylin drugs?", "acceptedAnswer": { "@type": "Answer", "text": "Pep19 is a research peptide studied in preclinical models. An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss." } }, { "@type": "Question", "name": "Those interested in visceral-fat-specific or lean-mass-sparing weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Pep19 is a research peptide studied in preclinical models. An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss." } }, { "@type": "Question", "name": "Researchers following endocannabinoid-system and intracellular-peptide pharmacology?", "acceptedAnswer": { "@type": "Answer", "text": "Pep19 is a research peptide studied in preclinical models. An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss." } }, { "@type": "Question", "name": "People asking whether a peptide can improve both metabolism and sleep?", "acceptedAnswer": { "@type": "Answer", "text": "Pep19 is a research peptide studied in preclinical models. An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss." } } ] } ] ```